Key Points
- Ellipses Pharma is exploring a London Stock Exchange listing through a proposed reverse takeover by Wolfram Resources.
- The company has been reported as targeting a valuation of between £450 million and £500 million.
- The proposed transaction is intended to bring Ellipses Pharma’s clinical-stage oncology portfolio to London’s Main Market.
- An equity fundraising is expected alongside the transaction, which is targeted for completion in early 2027.
- Final terms have not been agreed, and completion remains subject to due diligence, approvals and shareholder consent.
London (East London Times) November 18, 2026 – British cancer drug developer Ellipses Pharma said it is exploring a listing on the London Stock Exchange through a proposed reverse takeover by Wolfram Resources Plc. The transaction would involve Wolfram acquiring the entire issued share capital of Ellipses Pharma and seeking to re-list the enlarged group on the Main Market. The companies said an equity fundraising is also expected, with completion currently targeted for early 2027.
What is Ellipses Pharma proposing?
Ellipses Pharma and Wolfram Resources have signed a non-binding memorandum of understanding covering the proposed acquisition and re-listing. Consideration is expected to be satisfied through the issue of new Wolfram ordinary shares, although the final terms will be agreed after technical, financial and legal due diligence.
Ellipses Pharma’s pipeline includes clinical programmes targeting non-small-cell lung cancer and breast cancer. The proposed transaction would bring its clinical-stage oncology portfolio to the Main Market in the commercial companies listing category.
What valuation and timetable have been reported?
Reuters reported that Ellipses Pharma is targeting a valuation of between £450 million and £500 million, equivalent to approximately $594 million to $660 million. The report attributed the valuation range to an earlier Times report.
The companies said they are targeting completion of the proposed acquisition, fundraising and re-listing in early 2027. Business Live previously reported that the transaction could take place as early as February and that Berenberg was reported to have been appointed to oversee the deal, although those details were not included in the companies’ formal announcement.
What approvals are still required?
Wolfram Resources said the transaction remains conditional on satisfactory due diligence, agreement of final terms and definitive documentation. It also requires Financial Conduct Authority approval and publication of a prospectus, shareholder approval, relevant approval from the Panel on Takeovers and Mergers, and admission of the enlarged share capital to the Official List and the London Stock Exchange Main Market.
The companies cautioned that there is no certainty the proposed transaction will proceed or that it will proceed on the terms currently under consideration.
Why is the proposed listing significant?
Ellipses Pharma founder and chair Sir Chris Evans said a reverse takeover listing could help the company raise additional capital from public-market investors. The fundraising would give the clinical-stage developer access to capital markets while it advances its oncology programmes, although the amount and terms of any fundraising have not been disclosed.
What is the background to Ellipses Pharma’s development?
Ellipses Pharma was established in 2017 as a London-based global oncology drug development company. Its development pipeline includes programmes for non-small-cell lung cancer and breast cancer. Wolfram Resources is a Main Market-listed special purpose acquisition company whose shares have traded in the shell companies category. The proposed deal would change the enlarged group’s intended listing category to commercial companies, subject to regulatory and shareholder approvals.
How could the development affect Ellipses Pharma’s London listing audience?
For investors who follow British cancer drug developer Ellipses Pharma considers London listing developments, the proposed transaction could provide a public-market route to exposure to a clinical-stage oncology business. The expected fundraising may increase the company’s available capital, but it could also affect ownership through the issue of new shares.
London-listed biotechnology investors are likely to assess the company’s clinical evidence, development timetable, funding requirements and regulatory risks before any investment decision. Because the valuation, fundraising terms and definitive transaction documents have not been agreed, the potential effect on the company and its prospective audience cannot yet be determined.
